AHA 2019 | GALILEO-4D: Rivaroxaban in the Prevention of Post TAVR Valve Thickening and Thrombosis

This sub study of the GALILEO specifically looked at valve thickening and reduced leaflet motion after TAVR documented with 4D CT. Whether anticoagulation with rivaroxaban might reduce or prevent this phenomenon remained unanswered. 

AHA 2019 | GALILEO-4D:  rivaroxabán y prevención de engrosamiento y trombosis de las valvas post TAVI

Patients receiving the same anticoagulation scheme than the general study’s (rivaroxaban + aspirin vs. aspirin + clopidogrel) were assessed by 4D CT at 90±15 days after randomization. Primary end point was percentage of patients with at least one leaflet with reduced motion. Valve thickening was also assessed.

The study included 231 patients; 2.1% in the rivaroxaban group showed leaflet motion reduction in at least one valve vs. 10.9% in the antiplatelet antiaggregation group (p=0.01).


Read also: AHA 2019 | ISCHEMIA: The Invasive Approach (PCI or Surgery) Results Similar to Optimal Medical Treatment.


Thickening of at least one valve was observed in 12.4% of the rivaroxaban group vs. 32.4% in the antiplatelet antiaggregation group. 

Despite the above mentioned, in the general GALILEO study, the risk of death, thrombotic events and bleeding resulted higher in patients receiving rivaroxaban.

Conclusion

In patients undergoing TAVR with no formal anticoagulation indication, indicating rivaroxaban vs. antiplatelet antiaggregation was shown more effective in the prevention of valve motion subclinical abnormalities. However, the general study showed rivaroxaban was associated to higher mortality, thrombosis and bleeding rates. 

galileo-4d-aha2019

Original Title: Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement.

Reference: Ole De Backer et al. Presentado en el congreso AHA 2019 y publicado simultáneamente en NEJM.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...